PHARMACOKINETICS OF A NEW PLATINUM COMPOUND, -1,3-DIOXOLANE-2-SPIRO-1'-CYCLOHEXANE]PLATINUM(II) IN DOGS

A pharmacokinetic study on -1,3-dioxolane-2-spiro-1'-cyclohexane]plati num(II) (SKI 2032R) was performed in dogs. A single dose of 2.0 mg/kg of SKI 2032R was administered i.v. bolus to three beagle dogs. Plasma samples were analyzed for platinum by flameless atomic absorption spec trophotometry. Plasma concentrations of total and ultrafiltrable plati num for SKI 2032R declined in a biexponential fashion. The mean area u nder the concentration-time curve (AUC(0-->infinity)) determined for u ltrafiltrable platinum derived from SKI 2032R, as an active component, was 2.36 +/- 0.23 mu g . h/ml (mean +/- S.D.), with an initial half-l ife of 0.23 +/- 0.20 hour, a terminal half-life of 1.32 +/- 0.49 hour, a total clearance of 14.17 +/- 1.50 ml/min/kg, and a steady-state vol ume of distribution of 1.21 +/- 0.24 l/kg.